Cerdulatinib (PRT062070), an inhibitor of SYK and the Janus kinases JAK1/3, inhibits BCR- along with IL4-mediated signaling in CLL cells and reduces CCL3/CCL4 production to overcome stromal support (96). This evidence concerns the gene CCL3 and B-cell chronic lymphocytic leukemia.